Amylyx Pharmaceuticals

Q2 FY2026 EarningsQ2 FY2026 missed consensus as net loss per share of -$0.39 was wider than the -$0.36 expected. Revenue remained at zero in-line with forecasts following the AMX0035 withdrawal. Operating expenses rose to $45.7M, driven by a 40% YoY surge in SG&A to $21.9M for pre-commercial activities. The pivotal Phase 3 LUCIDITY trial for avexitide remains on track for topline data in late August/early September 2026, which is the primary near-term catalyst.